224 related articles for article (PubMed ID: 32947313)
21. Role of Radiation in Treatment of Renal Cell Carcinoma.
Leeman JE
Hematol Oncol Clin North Am; 2023 Oct; 37(5):921-924. PubMed ID: 37246085
[TBL] [Abstract][Full Text] [Related]
22. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.
All S; Garant A; Hannan R
Semin Radiat Oncol; 2021 Jul; 31(3):227-234. PubMed ID: 34090649
[TBL] [Abstract][Full Text] [Related]
24. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease.
Alongi F; Arcangeli S; Triggiani L; Mazzola R; Buglione di Monale E Bastia M; Fersino S; Baiguini A; Jereczek-Fossa BA; Magrini SM;
Crit Rev Oncol Hematol; 2017 Sep; 117():48-56. PubMed ID: 28807235
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Stereotactic Radiosurgery for Renal Cell Carcinoma Brain Metastases.
Haque W; Verma V; Butler EB; Teh BS
Clin Genitourin Cancer; 2018 Aug; 16(4):e935-e943. PubMed ID: 29680768
[TBL] [Abstract][Full Text] [Related]
28. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
29. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases.
Kothari G; Louie AV; Pryor D; Vela I; Lo SS; Teh BS; Siva S
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S17. PubMed ID: 28917255
[TBL] [Abstract][Full Text] [Related]
31. Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.
Maclean J; Breau RH; Scheida N; Malone S
BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25199199
[TBL] [Abstract][Full Text] [Related]
32. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review.
Dengina N; Tsimafeyeu I; Mitin T
Clin Genitourin Cancer; 2017 Apr; 15(2):183-187. PubMed ID: 27789182
[TBL] [Abstract][Full Text] [Related]
33. The role of stereotactic ablative body radiotherapy in renal cell carcinoma: focus on oligometastatic and oligoprogressive disease.
Marandino L; Ciccarese C; Francolini G; Amparore D; Campi R;
Minerva Urol Nephrol; 2023 Apr; 75(2):260-264. PubMed ID: 36999845
[No Abstract] [Full Text] [Related]
34. Stereotactic body radiation therapy for kidney cancer. Where do we stand?
Sosa-Fajardo P; Blanco-Suarez JM; Pineda-Munguía Á; Rubí-Olea L; Peleteiro-Higuero P; Gajate P; Zafra-Martín J; Siva S; Bossi A; López-Campos F; Couñago F
Int J Urol; 2023 May; 30(5):437-445. PubMed ID: 36746747
[TBL] [Abstract][Full Text] [Related]
35. [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
Müller AC; van Oorschot B; Micke O; Guckenberger M
Strahlenther Onkol; 2018 Jan; 194(1):1-8. PubMed ID: 28819766
[TBL] [Abstract][Full Text] [Related]
36. Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report.
Ma MW; Wang ZS; Li HZ; Gao XS; Liu C; Ren XY; Zhang WL; Yang KW
Med Dosim; 2024 Spring; 49(1):41-45. PubMed ID: 37563017
[TBL] [Abstract][Full Text] [Related]
37. Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer.
Yim K; Leeman JE
Urol Clin North Am; 2023 May; 50(2):325-334. PubMed ID: 36948675
[TBL] [Abstract][Full Text] [Related]
38. The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.
Wei Q; He H; Lv L; Xu X; Sun W
Transl Androl Urol; 2020 Dec; 9(6):2821-2830. PubMed ID: 33457253
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
40. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
